TSX seen lower ahead of Canadian GDP, U.S. PCE data
Investing.com -- Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) climbed 7% following the company’s announcement of securing an exclusive license to a method of treatment patent for its drug candidate, simufilam. The patent is related to potential treatments for seizures associated with rare neurodevelopmental disorders, including tuberous sclerosis complex (TSC).
The licensed patent, issued to Yale University, is grounded in the work of Dr. Angélique Bordey and her team. Their research, published in Science Translational Medicine in 2020, demonstrated that simufilam significantly reduced seizure frequency in an animal model of TSC. This development could pave the way for a new therapeutic application for simufilam, expanding its potential beyond its current investigational uses for central nervous system (CNS) disorders.
Rick Barry, President and CEO of Cassava Sciences, expressed optimism about the agreement with Yale University, stating, "We plan to conduct preclinical studies in collaboration with the TSC Alliance to further evaluate simufilam’s potential as a treatment for TSC-related seizures and define next steps." This strategic move by Cassava has sparked investor interest, as it suggests the company is actively broadening its research pipeline and seeking to address unmet medical needs in the field of neurodevelopmental disorders.
The stock’s upward movement reflects the market’s positive reception to Cassava’s expansion of its intellectual property portfolio and its potential to unlock new markets for simufilam. The agreement with Yale represents a significant milestone for Cassava, as it not only secures the rights to a promising therapeutic method but also strengthens the company’s position in the biotechnology industry, particularly within the realm of CNS disorder treatments.
Investors will be watching closely as Cassava Sciences continues its preclinical studies and progresses toward defining the clinical pathway for simufilam in the treatment of TSC-related seizures. The company’s collaboration with the TSC Alliance is also a key factor in advancing this research and potentially bringing a new treatment option to patients with these rare disorders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.